Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 8/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | GALR1 | P47211 | 1/20 | 0.39 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 3/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5554946 | 0.81 | CCNA2 (0.39) | CCNA2CDK2CCNA1CCNB2CDK1 | |
| SCHEMBL5555610 | 0.79 | GBA1 (0.43) | CCNA2CDK2CCNA1CCNB2CDK1 | |
| SCHEMBL5032362 | 0.79 | GALR1 (0.60) | PRKCQCDK2CDK1CCNB1GALR1 | |
| SCHEMBL14300360 | 0.79 | GALR1 (0.44) | PRKCQCDK2CDK1CCNB1GALR1 | |
| SCHEMBL5549956 | 0.78 | EGFR (0.42) | CCNA2CDK2CCNA1CCNB2CDK1 | |
| SCHEMBL5555616 | 0.77 | GBA1 (0.44) | CCNA2CDK2CCNA1CCNB2CDK1 | |
| SCHEMBL6428019 | 0.76 | FLT3 (0.40) | PRKCQCCNA2CDK2CCNA1CCNB2 | |
| SCHEMBL5549907 | 0.76 | VNN1 (0.42) | CDK1GBA1GALR1 | |
| SCHEMBL6016938 | 0.75 | GBA1 (0.42) | GBA1 | |
| SCHEMBL6428767 | 0.73 | VNN1 (0.43) | CCNA2CDK2CCNA1CCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | PRKCQ 2518/4885CCNA2 2119/4885CDK2 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.